Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +36.41%
#3 Bedrock Bedrock +19.79%
#4 Cysic Cysic +17.50%
#5 Fabric Protocol Fabric Protocol +12.90%
#6 stake.link stake.link +8.07%
#7 Velvet Velvet +6.50%
#8 Pons Pons +5.95%
#9 Perle Perle +5.89%
#10 Cap Cap +5.67%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
株式のランク #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
株価
$0.051239
最終同期: 2025-11-24
時価総額
$1.38M
変化（1日）
-4.48%
変化（1年）
-54.57%
国
NO
取引 BerGenBio ASA (BGBIO)

カテゴリー

Healthcare
BerGenBio ASA（BGBIO）の配当利回りの履歴
BerGenBio ASA（銘柄コード: BGBIO）の配当利回り（TTM）は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
BerGenBio ASA（BGBIO）の2026から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
年 配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り（TTM）
企業 配当利回り 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
0.65%
BE